Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Find Drugs in Development News & Deals for Aspirin

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

JDMFs Filed

JDMFs Filed

EU WC

EU WC

Listed Suppliers

Listed Suppliers

API REF. PRICE (USD / KG)
7
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

JP

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • CAPSULE;ORAL - 356.4MG;30MG;16MG
  • TABLET;ORAL - 325MG;50MG;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • CAPSULE;ORAL - 325MG;50MG;40MG;30MG
  • TABLET, DELAYED RELEASE;ORAL - 325MG;40MG
  • TABLET, DELAYED RELEASE;ORAL - 81MG;40MG
  • TABLET;ORAL - 250MG;250MG;65MG
  • CAPSULE, EXTENDED RELEASE;ORAL - 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - 325MG;50MG;40MG

Details:

The US Food & Drug Administration (US FDA) has approved Abbreviated New Drug Application (ANDA) for Acetaminophen, Aspirin and Caffeine Tablets USP, 250 mg/250 mg/65 mg (OTC).


Lead Product(s): Paracetamol,Aspirin,Caffeine

Therapeutic Area: Neurology Product Name: Acetaminophen/Aspirin/Caffeine-Generic

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 24, 2021

Granules India

WBC 2024

Not Confirmed

envelop Contact Supplier

Details:

Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagulation.


Lead Product(s): Rivaroxaban,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 09, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.


Lead Product(s): Aspirin,Ramipril,Simvastatin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Polypill

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: CNIC

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral anticoagulant (NOAC) worldwide and is marketed under the brand name Xarelto. Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions.


Lead Product(s): Rivaroxaban,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 21, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

VAZALORE is an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. VAZALORE delivers aspirin differently from plain and enteric coated aspirin products.


Lead Product(s): Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vazalore

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

COMPASS open label extension study results support the long-term use of XARELTO (rivaroxaban) plus aspirin for vascular protection in patients with chronic CAD and/or PAD.


Lead Product(s): Rivaroxaban,Aspirin

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Xarelto

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 23, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD).


Lead Product(s): Rivaroxaban,